NephroDi Therapeutics

Executive Summary

NephroDI Therapeutics is a Boston-based preclinical biopharmaceutical company developing first-in-class small molecule therapies for rare kidney concentration disorders, with a lead program targeting congenital nephrogenic diabetes insipidus (NDI) in children. Founded in 2019 from academic research at Emory University and Georgia Tech, the company is advancing an oral AMPK activator designed to address the underlying defect in renal water reabsorption. NDI is a debilitating condition characterized by excessive thirst and urination, leading to dehydration and electrolyte imbalances, with no approved therapies specifically for the congenital form. NephroDI's approach has the potential to be the first disease-modifying treatment, offering a significant improvement over current symptomatic management. The company is currently in preclinical development, and its progress will depend on successful completion of IND-enabling studies and securing partnerships or funding for clinical trials. Given the high unmet need and novel mechanism, NephroDI represents an early-stage opportunity with substantial upside but also significant technical and regulatory risk.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Proof-of-Concept Data Release60% success
• Q4 2026IND Filing for Lead Program30% success
• H2 2026Series A Financing or Strategic Partnership40% success